Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
Marinus Pharmaceuticals, a leader in therapeutics for seizure disorders, announced its participation in several key investor and medical conferences in May and June.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Citi Biotech Virtual Co-Panel Day
This presentation will be closed to conference participants only.
Available on demand starting
Webcast Link: https://journey.ct.events/view/f447a79f-2d56-40f1-9924-e6b53707d9c1
Webcast Link: https://wsw.com/webcast/jeff240/mrns/1869600
16th
This event is closed to conference participants only.
This presentation will be closed to conference participants only.
About
Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005448/en/
Vice President, Corporate Affairs & Investor Relations
484-253-6792
sdamouni@marinuspharma.com
Source: